Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CanSino BiologicsCASBF +20.96%65 Net Cash per Share is $0.23 as of Dec. 2025, which is 99% below its 10-year median of 19.29. GuruFocus rates CASBF with a GF Score™ of 65/100 and a GF Value™ of $8.99 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 252 Drug Manufacturers companies, CanSino Biologics ranks worse than 63.1% on this metric.
CanSino Biologics (OTCPK:CASBF) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
CanSino Biologics Net Cash per Share Related Terms
CanSino Biologics Net Cash per Share Historical Data
* Premium members only.
The historical data trend for CanSino Biologics's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanSino Biologics Price-to-Net-Cash vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where CanSino Biologics's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
CanSino Biologics's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CanSino Biologics (CASBF) has a Net Cash per Share of $0.23 as of Dec. 2025. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on CanSino Biologics and its competitors. This is 99% below median its historical median of 19.29. Over the past decade, CanSino Biologics' Net Cash per Share has ranged from 8.29 to 69.26. According to the industry distribution chart, CanSino Biologics ranks #159 out of 252 companies in the Drug Manufacturers industry, placing it in the top 63.1%.
Is CanSino Biologics' Net Cash per Share too high?
CanSino Biologics' current Net Cash per Share of $0.23 is 99% below median its 10-year median of 19.29. Over the past 10 years, this metric has ranged from a low of 8.29 to a high of 69.26. The Drug Manufacturers industry median Net Cash per Share is 8.66. CanSino Biologics' value of $0.23 is 97.3% below this industry median. Based on the distribution chart, CanSino Biologics ranks #159 out of 252 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, CanSino Biologics has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CanSino Biologics' Net Cash per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CanSino Biologics ranks #159 out of 252 companies for Net Cash per Share. This places CanSino Biologics in the lower half of its industry. The industry median Net Cash per Share is 8.66. CanSino Biologics' value of $0.23 is 97.3% below this benchmark. Historically, CanSino Biologics' own Net Cash per Share has ranged from 8.29 to 69.26 over the past decade. While the company's 10-year median is 19.29 vs. the industry median of 8.66, CanSino Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Drug Manufacturers company?
The median Net Cash per Share among Drug Manufacturers companies is 8.66, based on 252 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CanSino Biologics's current Net Cash per Share of $0.23 is 97.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on CanSino Biologics and its competitors. For the Drug Manufacturers industry, the median Net Cash per Share is 8.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanSino Biologics's current Net Cash per Share is $0.23, which is 99% below median its own 10-year median of 19.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanSino Biologics stock overvalued right now?
Based on GuruFocus' analysis, CanSino Biologics (CASBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $8.99, compared to a current price of $3.15 — trading 65% below its estimated fair value. The current Net Cash per Share is $0.23, which is 99% below median its 10-year median of 19.29 and 97.3% below the Drug Manufacturers industry median of 8.66. CanSino Biologics' overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For CanSino Biologics (CASBF), the current Net Cash per Share is $0.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CanSino Biologics (CASBF) Overvalued in 2026?
Based on GuruFocus' analysis, CanSino Biologics stock appears to be undervalued.
The current stock price of $3.15 is trading 65% below its estimated GF Value™ of $8.99.
GuruFocus considers CanSino Biologics to be Significantly Undervalued.
Key valuation signals for CASBF:
Net Cash per Share: $0.23 (99% below median its 10-year median of 19.29)
GF Value™: $8.99 vs. price of $3.15 (65% below fair value)
Industry Position: 97.3% below the Drug Manufacturers median (#159 of 252)
No single metric tells the full story. See the CASBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CanSino Biologics Inc is engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. The company has a broad portfolio of vaccines and vaccine candidates for several disease areas. Its commercial-stage products are Menhycia and Menphecia, iPneucia, Convidecia and Convidecia Air, and XBB.1.5 Variant, and Ad5-EBOV. The company's clinical-stage products include Tetanus Vaccine, DTcP Infant, Tdcp Adolescent and Adult, Recombinant Poliomyelitis Vaccine, PBPV, and Recombinant Zoster Vaccine, among others. Additionally, it has various vaccine candidates in pre-clinical programs, targeting diseases such as influenza, meningitis, pneumonia, and others. Geographically, the company generates maximum revenue from the People's Republic of China.
65GF Score
Get the complete analysis for CASBF
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CASBF has been successfully added to your 
